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Abstract 
The lymphocyte depletion classical Hodgkin 
lymphoma (LDCHL) is the less common subtype of 
cHL. In LDCHL, Hodgkin and Reed-Sternberg 
(HRS) cells grow within a background depleted in 
reactive lymphocytes. LDCHL subtype accounts for 
only a small fraction of all HL cases in Western 
countries. It also occurs in people with HIV/AIDS. 
The HRS cells show the same immunophenotype as 
in the other subtypes of cHL. 
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Identity 
Other names 
Lymphocyte depletion Hodgkin Lymphoma 
Lymphocyte-depleted classical Hodgkin lymphoma 
Lymphocyte depletion Hodgkin disease. 
Clinics and pathology 
Disease 
Hodgkin Lymphoma (HL) includes classical 
Hodgkin lymphoma (CHL) which accounts for 95% 
of all cases (Stein et al. 2008). Lymphocyte depletion 
classical Hodgkin lymphoma (LDCHL) is the less 
common subtype of cHL (Benharroch et al., 2008). 
LDCHL is a subtype of cHL rich in Hodgkin and 
Reed-Sternberg (HRS) cells. These cells reside 
within a background depleted in non-neoplastic 
lymphocytes. In the past few decades, a fraction of 
these cases have been reclassified into different non-
Hodgkin lymphoma entities (Benharroch et al., 
2008). 
Phenotype/cell stem origin 
LDCHL involves a clonal expansion of germinal 
center B-cell derived lymphocytes which mimic 
those observed in the other subtypes of cHL. 
Epidemiology 
LDCHL accounts for only a small fraction, less than 
1%, of all HL cases in Western countries. There is a 
male predominance. The median age ranges from 30 
to 40 years. LDCHL is often seen in people infected 
with HIV and more often in developing countries 
(IARC, 2012). 
People with HIV/AIDS are at increased risk of HL 
in the highly active antiretroviral therapy era. In 
HIV-infected people cHL is presently the most 
common non-AIDS defining cancer (Carbone et al., 
2014). 
Clinics 
Patients affected by LDCHL present with an 
advanced stage (III-IV stage) and with B symptoms 
more often than those affected by the other subtypes. 
LDCHL usually involves retroperitoneal lymph-
nodes and extranodal sites including abdominal 
organs and bone-marrow (Younes et al., 2014). 
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Figure 1. Involvement of lymph node by HIV-associated classic Hodgkin lymphoma (cHL) of the lymphocyte depletion subtype. 
Large Hodgkin Reed-Sternberg (HRS) cells with multiple nuclei and prominent nucleoli are present. HRS cells express the 




Figure 2. Involvement of lymph node by HIV-associated classic Hodgkin lymphoma (cHL) of the lymphocyte depletion subtype. 
Large Hodgkin Reed-Sternberg (HRS) cells are Epstein-Barr virus-infected as demonstrated by EBER in situ hybridization 
(brown) with latent membrane protein 1 expression (red). 
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Pathology 
A consistent feature is the predominance of HRS 
cells in relation to the cell density of the background. 
The HRS cells are pleomorphic with a sarcomatous 
appearance. A proportion of HRS cells may 
resemble anaplastic forms of tumour cells observed 
in some large cell non-Hodgkin lymphoma. The 
background is characterized by diffuse fibrosis and 
depletion in reactive lymphocytes. 
Phenotype 
The HRS cells show the same immunophenotype as 
in the other subtypes of CHL (Carbone and Gloghini, 
2016); the immunophenotype is the following: 




Tumour tissue is characterized by an unusual large 
proportion of HRS cells infected by EBV. EBV is 
found in nearly all cases of LDCHL occurring in 
patients infected by HIV. EBV infected tumour cells 
contain LMP1 which can activate critical signaling 
pathways including NF-kB. 
It seems appropriate to mention here that the 
virologic characteristics of HL vary according to the 
immunocompetence status of the host and cHL 
subtype (IARC, 2012; Swerdlow et al., 2008) as 
follows: 
cHL of the general population 
- NS cHL, usually EBV negative 
- MC cHL, usually EBV positive 
- LRCHL, variably EBV positive 
- LD cHL, variably EBV positive 
Immunodeficiency-associated cHL 
- HIV-associated cHL, EBV positive 
- Post-transplant cHL, EBV positive 
- Iatrogenic (methotrexate), variaby EBV positive 
Etiology  
LMP1 expression is observed in virtually all HIV 
associated LDCHL cases: it suggests that EBV play 
an etiological role in the pathogenesis of these 
tumours. 
 Cell microenvironment  
HRS cells are usually seen in a microenvironment 
where several histiocytoid cells are admixed with 
few small lymphocytes. These lymphocytes 
predominantly express the CD3+, CD4+, CD8-/+, 
CD20- phenotype. 
It has been recognized that EBV has the capability to 
modulate the tumour microenvironment (Dolcetti, 
2015; Dolcetti et al., 2016). 
Treatment 
The combination of cART with better supportive 
therapy has made standard ABVD (doxorubicin,  
bleomycin, vinblastine, dacarbazine), used for 
LDCHL occurring in the general population, feasible 
in patients with HIV-associated Hodgkin lymphoma 
(Carbone et al., 2014). 
Prognosis 
Most patients affected by LDCHL have a worse 
prognosis than do patients affected by other cHL 
subtypes (Younes et al., 2012). 
Poor prognosis have been observed in patients 
affected by HIV-associated LDCHL. The outcome 
of HIV-associated cHL has dramatically improved 
since the introduction of cART with intensive 
chemotherapy regimens (Carbone et al., 2014). 
Genetics 
Due to the small number of LDCHL cases analysed 
for genetics/cytogenetics characteristics and to the 
reclassification of cases into different lymphoma 
categories, the previously described genetics and 
cytogenetics findings are not unquestionably 
acknowledged. 
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